Jefferies Group LLC reiterated their buy rating on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in a research report released on Saturday, July 22nd. They currently have a $36.00 target price on the stock.
A number of other equities research analysts have also issued reports on the company. Cann reissued a market perform rating on shares of Intellia Therapeutics in a research note on Monday, July 17th. Credit Suisse Group set a $24.00 price target on Intellia Therapeutics and gave the stock a buy rating in a research note on Wednesday, May 3rd. Chardan Capital initiated coverage on Intellia Therapeutics in a research note on Monday, March 27th. They set a buy rating and a $19.00 price target for the company. They noted that the move was a valuation call. Wedbush reissued an outperform rating and set a $25.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, May 3rd. Finally, Zacks Investment Research lowered Intellia Therapeutics from a hold rating to a sell rating in a research note on Thursday, April 6th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $24.83.
Shares of Intellia Therapeutics (NTLA) traded down 0.36% during mid-day trading on Friday, reaching $16.49. The company’s stock had a trading volume of 157,436 shares. Intellia Therapeutics has a 52-week low of $10.83 and a 52-week high of $24.90. The company’s market cap is $595.49 million. The company has a 50-day moving average price of $16.53 and a 200 day moving average price of $14.41.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.03. The company had revenue of $5.90 million during the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The firm’s revenue for the quarter was up 40.5% on a year-over-year basis. Equities analysts expect that Intellia Therapeutics will post ($1.74) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/08/16/intellia-therapeutics-ntla-buy-rating-reaffirmed-at-jefferies-group-llc-updated-updated-updated.html.
In other Intellia Therapeutics news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total transaction of $2,436,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 12.80% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in shares of Intellia Therapeutics during the second quarter worth about $101,000. IHT Wealth Management LLC bought a new position in shares of Intellia Therapeutics during the first quarter worth about $117,000. Bank of Montreal Can increased its position in shares of Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after buying an additional 7,222 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of Intellia Therapeutics by 117.7% in the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock worth $129,000 after buying an additional 4,351 shares in the last quarter. Finally, Nisa Investment Advisors LLC bought a new position in shares of Intellia Therapeutics during the second quarter worth about $134,000. Institutional investors and hedge funds own 47.20% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
